Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Consolidation in Unresectable Stage III NSCLC
NCT07204548Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07204548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204548.